• Complete Response was the primary endpoint of this noninferiority trial^1,2
• The most common types of cancer for patients in this trial were breast, lung, colon/rectal, and bladder (≥5% of patients in any group)²
• The most common chemotherapy regimens for patients in this trial were cyclophosphamide, doxorubicin, cisplatin, and methotrexate (≥10% of patients in any
  group)²

Complete Response^1,2†

(No emetic episode and no use of rescue medication)

^* Double-blind, randomized, Phase III noninferiority trial comparing single doses of ALOXI with ondansetron following MEC with a primary endpoint of CR. p≤0.025 (adjusted post-hoc, 2-sided, Fisher’s exact test comparisons of ALOXI with ondansetron; 97.5% confidence interval [CI]).
^† ITT cohort

• A single IV dose of ALOXI provided significantly higher response rates vs ondansetron in both the acute and delayed phases and during the overall study period (p=0.0085, p<0.001, and p<0.001)^1,2
  • Clinical superiority over other 5-HT₃ receptor antagonists has not been adequately demonstrated in the acute phase¹

Significantly longer time to treatment failure vs ondansetron

Kaplan-Meier plot of time to treatment failure^2,3*

(First emetic episode or use of rescue medication)

* Double-blind, randomized Phase III noninferiority trial comparing single doses of ALOXI with ondansetron following MEC with a primary endpoint of CR and secondary endpoints that included time to treatment failure.
^† ITT cohort.

• Time to treatment failure (secondary endpoint) was significantly longer following treatment with ALOXI than ondansetron (p<0.001)^2,3
  • Median time to treatment failure was >120 hours in both treatment groups
  • Time to treatment failure in the first quartile was more than twice as long for ALOXI than ondansetron (46.5 hours vs 19.5 hours)
• A separation in control rates appeared as early as Day 1^2,3

ALOXI lasts long against nausea

Nausea-free patients^2,3†

* Double-blind, randomized, Phase III noninferiority trial comparing single doses of ALOXI with ondansetron following MEC with a primary endpoint of CR and secondary endpoints that included incidence of nausea.
^† Patients reported nausea using a 4-point Likert scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe. Only patients reporting “0 = none” were considered nausea-free.
^‡ ITT cohort.

• Significantly more patients who received ALOXI were nausea-free (secondary endpoint) on Days 2-4 following MEC than those who receive ondansetron²
• Patients ranked nausea as one of the most distressing side effects of chemotherapy.⁴